GSK Announced Phase 3 Prima Trial of Zejula is the First Study to Show a Parp Inhibitor Significantly Improves Pfs, Regardless of Biomarker Status, When Given as Monotherapy in Women With First-line Platinum Responsive Advanced Ovarian Cancer